173 related articles for article (PubMed ID: 29372356)
21. Evaluation of the 8th AJCC staging system for pathologically versus clinically staged pancreatic adenocarcinoma: A time to revisit a dogma?
Abdel-Rahman O
Hepatobiliary Pancreat Dis Int; 2018 Feb; 17(1):64-69. PubMed ID: 29428107
[TBL] [Abstract][Full Text] [Related]
22. Validation of the Prognostic Significance of the Prognostic Stage Group According to the Eighth Edition of American Cancer Joint Committee on Cancer Staging System in Triple-Negative Breast Cancer: An Analysis From Surveillance, Epidemiology, and End Results 18 Database.
Luo SP; Wu QS; Chen H; Wang XX; Chen QX; Zhang J; Song CG
J Surg Res; 2020 Mar; 247():211-219. PubMed ID: 31706539
[TBL] [Abstract][Full Text] [Related]
23. Validation of the American Joint Committee on Cancer eighth edition staging system in patients undergoing hepatectomy for hepatocellular carcinoma: a US population-based study.
Zhang G; Li R; Zhao X; Meng S; Ye J; Zhao L
J Surg Res; 2018 Feb; 222():55-68. PubMed ID: 29273376
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the current prostate cancer staging system based on cancer-specific mortality in the surveillance, epidemiology, and end results database.
Shukla ME; Yu C; Reddy CA; Stephans KL; Klein EA; Abdel-Wahab M; Ciezki J; Tendulkar RD
Clin Genitourin Cancer; 2015 Feb; 13(1):17-21. PubMed ID: 25571871
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Buyyounouski MK; Choyke PL; McKenney JK; Sartor O; Sandler HM; Amin MB; Kattan MW; Lin DW
CA Cancer J Clin; 2017 May; 67(3):245-253. PubMed ID: 28222223
[TBL] [Abstract][Full Text] [Related]
26. Modified the 8th AJCC staging system for patients with advanced prostate cancer: a study based on SEER database.
Sun C; Yang D; Zhu J; Zhou Y; Xiang C; Wu S
BMC Urol; 2022 Nov; 22(1):185. PubMed ID: 36384495
[TBL] [Abstract][Full Text] [Related]
27. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
Zagars GK; Pollack A
Urology; 1995 Mar; 45(3):476-83. PubMed ID: 7533459
[TBL] [Abstract][Full Text] [Related]
28. Gleason inflation 1998-2011: a registry study of 97,168 men.
Danneman D; Drevin L; Robinson D; Stattin P; Egevad L
BJU Int; 2015 Feb; 115(2):248-55. PubMed ID: 24552193
[TBL] [Abstract][Full Text] [Related]
29. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
30. Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease.
Han M; Walsh PC; Partin AW; Rodriguez R
J Urol; 2000 Jul; 164(1):89-92. PubMed ID: 10840430
[TBL] [Abstract][Full Text] [Related]
31. Challenging a dogma; AJCC 8th staging system is not sufficient to predict outcomes of patients with malignant pleural mesothelioma.
Abdel-Rahman O
Lung Cancer; 2017 Nov; 113():128-133. PubMed ID: 29110839
[TBL] [Abstract][Full Text] [Related]
32. Validation of the American Joint Committee on Cancer (AJCC) 8th edition stage system for gastric cancer patients: a population-based analysis.
He X; Wu W; Lin Z; Ding Y; Si J; Sun LM
Gastric Cancer; 2018 May; 21(3):391-400. PubMed ID: 29052053
[TBL] [Abstract][Full Text] [Related]
33. Validation of the Eighth AJCC New Substages for Bladder Cancer Among Different Staging Contexts.
Abdel-Rahman O
Clin Genitourin Cancer; 2017 Dec; 15(6):e1095-e1106. PubMed ID: 28843376
[TBL] [Abstract][Full Text] [Related]
34. Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base.
Miller DC; Hafez KS; Stewart A; Montie JE; Wei JT
Cancer; 2003 Sep; 98(6):1169-78. PubMed ID: 12973840
[TBL] [Abstract][Full Text] [Related]
35. Validation of the eighth clinical American Joint Committee on Cancer stage grouping for esophageal cancer.
Oweira H; Schmidt J; Mehrabi A; Kulaksiz H; Schneider P; Schöb O; Giryes A; Abdel-Rahman O
Future Oncol; 2018 Jan; 14(1):65-75. PubMed ID: 29235888
[TBL] [Abstract][Full Text] [Related]
36. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
37. A Gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy.
Green GA; Hanlon AL; Al-Saleem T; Hanks GE
Cancer; 1998 Sep; 83(5):971-6. PubMed ID: 9731902
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
Lau WK; Blute ML; Bostwick DG; Weaver AL; Sebo TJ; Zincke H
J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the eighth American Joint Committee on Cancer staging system for malignant melanoma of the skin.
Abdel-Rahman O
Future Oncol; 2018 Feb; 14(5):471-481. PubMed ID: 29322826
[TBL] [Abstract][Full Text] [Related]
40. Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.
Falchook AD; Martin NE; Basak R; Smith AB; Milowsky MI; Chen RC
Urol Oncol; 2016 Mar; 34(3):119.e19-26. PubMed ID: 26526383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
